Informations sur les membres
Dr Marta Morales Ballús
Espagne
ÉQUIPE
Dr Jaume Català Mora
Espagne
Dr Elisa Carreras
Espagne
Dr Itziar Alonso
Espagne
Dr Isabel Ayet
Espagne
Dr Ester Casas
Espagne
Optometrist Ana Díaz
Espagne
Dr Jesús Díaz
Espagne
Optometrist Enric Puigventos
Espagne
Optometrist Carles Fresno
Espagne
Dr Carmen García Vicuña
Espagne
Dr Hugo Gonzalez
Espagne
Optometrist Enrique Jimenez
Espagne
Dr Ana Llorca
Espagne
Dr Antonio Federico Martinez Monstseny
Espagne
Dr Joan Prat
Espagne
Dr Gemma Romeu
Espagne
Dr Alicia Serra
Espagne
Optometrist Simone Suh
Espagne
Dr Mariona Vidal
Espagne
Optometrist Begoña Yeste
Espagne
Dr Núria Planas
Espagne
Centre de soins de santé
contact
Hospital Sant Joan de Déu, Spain
Essais cliniques
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation